Daiichi Sankyo Company, Limited is Japan’s second-largest pharmaceutical corporation, celebrated globally as a pioneer in oncology and targeted biotherapeutics. The company engineered an industry-leading antibody-drug conjugate (ADC) franchise anchored by its proprietary DXd platform, producing breakthrough blockbusters like Enhertu (trastuzumab deruxtecan). However, this rapid ascent has created severe portfolio concentration risk, leaving overall financial performance disproportionately tied to clinical and commercial execution within a single modality. Outside oncology, Daiichi Sankyo manages legacy cardiovascular treatments such as Lixiana (edoxaban) and domestic Japanese generic/OTC lines, but these mature cash cows face patent expirations and strict governmental price cuts. Furthermore, while strategic co-commercialization pacts with Western giants have expanded global access, they force substantial profit-sharing arrangements and subject the enterprise to shared regulatory, production, and co-partner execution vulnerabilities.
Market position and competitiors
Below is a list of articles for the company:
-
Daiichi Sankyo – supply chain
Market Position and Market Share Daiichi Sankyo Company, Limited ranks as the 2nd largest pharmaceutical company in Japan by market capitalization (following Takeda Pharmaceutical) and has emerged as the global leader in the next-generation Antibody-Drug Conjugate (ADC) oncology landscape. Supply Chain Upstream, Downstream, and Key Suppliers The ADC supply chain is among the most intricate…
-
Daiichi Sankyo – business model
Company History Foundation and Merger Phase (1899–2005) Sankyo was originally founded in 1899, establishing its legacy through digestive enzymes and later statins, while Daiichi Pharmaceutical was founded in 1915, specializing in anti-infectives and synthetic medicines. Both entities grew into cornerstone Japanese pharmaceutical houses throughout the 20th century. In September 2005, facing intensifying global consolidation and…